Repeated exposure to 5D9, an inhibitor of 3D polymerase, effectively limits the replication of foot-and-mouth disease virus in host cells

Antiviral Research

Volumn 98, Issue 3, 2013, Pages 380-385

  Rai, Devendra K ^a   Schafer, Elizabeth A ^a   Singh, Kamalendra ^b   McIntosh, Mark A ^b   Sarafianos, Stefan G ^b,c   Rieder, Elizabeth ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^b University of Missouri   (United States)

^c Department of Biochemistry ^*  (United States)

Author keywords

3D polymerase inhibitor; 5D9 compound; Antiviral; FMDV therapeutic treatment; Foot and mouth disease virus (FMDV)

Indexed keywords

2' METHYLCYTIDINE; 4 CHLORO N' THIENO, [2,3 D]PYRIMIDIN 4 YLBENZENESULFONOHYDRAZIDE; 5D9; ANTIVIRUS AGENT; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; FOOT AND MOUTH DISEASE VIRUS; HELA CELL; HOST CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS CELL INTERACTION; VIRUS ISOLATION; VIRUS REPLICATION;

ANIMALS; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CELL LINE; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; FOOT-AND-MOUTH DISEASE VIRUS; HETEROCYCLIC COMPOUNDS, 2-RING; INHIBITORY CONCENTRATION 50; MICROBIAL VIABILITY; RIBAVIRIN; SERIAL PASSAGE; SULFONAMIDES; TIME FACTORS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PLAQUE ASSAY; VIRUS REPLICATION;

FOOT-AND-MOUTH DISEASE VIRUS; RNA VIRUSES;

EID: 84877097581     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.03.022     Document Type: Article

References (50)

1. Agudo R., Ferrer-Orta C., Arias A., de la Higuera I., Perales C., Perez-Luque R., Verdaguer N., Domingo E. A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog. 2010, 6(8):e1001072.
2. Airaksinen A., Pariente N., Menendez-Arias L., Domingo E. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 2003, 311(2):339-349.
3. Aloia A.L., Locarnini S., Beard M.R. Antiviral resistance and direct-acting antiviral agents for HCV. Antivir. Ther. 2012, 17(6 Pt B):1147-1162.
4. Arias A., Arnold J.J., Sierra M., Smidansky E.D., Domingo E., Cameron C.E. Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J. Virol. 2008, 82(24):12346-12355.
5. Bachrach H.L. Foot-and-mouth disease. Annu. Rev. Microbiol. 1968, 22:201-244.
6. Belsham G.J. Dual initiation sites of protein synthesis on foot-and-mouth disease virus RNA are selected following internal entry and scanning of ribosomes in vivo. EMBO J. 1992, 11(3):1105-1110.
7. Bentham M., Holmes K., Forrest S., Rowlands D.J., Stonehouse N.J. Formation of higher-order foot-and-mouth disease virus 3D(pol) complexes is dependent on elongation activity. J. Virol. 2012, 86(4):2371-2374.
8. Bruenn J.A. A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases. Nucl. Acids Res. 2003, 31(7):1821-1829.
9. Castro C., Arnold J.J., Cameron C.E. Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res. 2005, 107(2):141-149.
10. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000, 6(12):1375-1379.
11. De Clercq E. Antiviral drug discovery and development: where chemistry meets with biomedicine. Antiviral Res. 2005, 67(2):56-75.
12. Dias C.C., Moraes M.P., Segundo F.D., de los Santos T., Grubman M.J. Porcine type I interferon rapidly protects swine against challenge with multiple serotypes of foot-and-mouth disease virus. J. Interferon Cytokine Res. 2011, 31(2):227-236.
13. Dias C.C., Moraes M.P., Weiss M., Diaz-San Segundo F., Perez-Martin E., Salazar A.M., de los Santos T., Grubman M.J Novel antiviral therapeutics to control foot-and-mouth disease. J Interferon Cytokine Res 2012, 32(10):462-473.
14. Domingo E. RNA virus evolution and the control of viral disease. Prog. Drug Res. 1989, 33:93-133.
15. Domingo E. RNA virus evolution, population dynamics, and nutritional status. Biol. Trace Elem. Res. 1997, 56(1):23-30.
16. Domingo E., Escarmis C., Sevilla N., Moya A., Elena S.F., Quer J., Novella I.S., Holland J.J. Basic concepts in RNA virus evolution. FASEB J. 1996, 10(8):859-864.
17. Durk R.C., Singh K., Cornelison C.A., Rai D.K., Matzek K.B., Leslie M.D., Schafer E., Marchand B., Adedeji A., Michailidis E., Dorst C.A., Moran J., Pautler C., Rodriguez L.L., McIntosh M.A., Rieder E., Sarafianos S.G. Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase. PLoS ONE 2010, 5(12):e15049.
18. Elena S.F., Sanjuan R. RNA viruses as complex adaptive systems. Biosystems 2005, 81(1):31-41.
19. Elena S.F., Carrasco P., Daros J.A., Sanjuan R. Mechanisms of genetic robustness in RNA viruses. EMBO Rep. 2006, 7(2):168-173.
20. Ferrer-Orta C., Arias A., Perez-Luque R., Escarmis C., Domingo E., Verdaguer N. Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J. Biol. Chem. 2004, 279(45):47212-47221.
21. Ferrer-Orta C., Arias A., Agudo R., Perez-Luque R., Escarmis C., Domingo E., Verdaguer N. The structure of a protein primer-polymerase complex in the initiation of genome replication. EMBO J. 2006, 25(4):880-888.
22. Ferrer-Orta C., Arias A., Perez-Luque R., Escarmis C., Domingo E., Verdaguer N. Sequential structures provide insights into the fidelity of RNA replication. Proc. Natl. Acad. Sci. USA 2007, 104(22):9463-9468.
23. Ferrer-Orta C., Sierra M., Agudo R., de la Higuera I., Arias A., Perez-Luque R., Escarmis C., Domingo E., Verdaguer N. Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J. Virol. 2010, 84(12):6188-6199.
24. Furio V., Moya A., Sanjuan R. The cost of replication fidelity in an RNA virus. Proc. Natl. Acad. Sci. USA 2005, 102(29):10233-10237.
25. Ghoneim N.H., Abdel-Karim A.K., El-Shehawy L., Abdel-Moein K.A. Foot and mouth disease in animals in Sharkia governorate - Egypt. Transbound Emerg. Dis. 2010, 57(1-2):19-21.
26. Gnadig N.F., Beaucourt S., Campagnola G., Borderia A.V., Sanz-Ramos M., Gong P., Blanc H., Peersen O.B., Vignuzzi M. Coxsackievirus B3 mutator strains are attenuated in vivo. Proc. Natl. Acad. Sci. USA 2012, 109(34):E2294-E2303.
27. Gong P., Peersen O.B. Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase. Proc. Natl. Acad. Sci. USA 2010, 107(52):22505-22510.
28. Goris N., De Palma A., Toussaint J.F., Musch I., Neyts J., De Clercq K. 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 2007, 73(3):161-168.
29. Grubman M.J. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals 2005, 33(4):227-234.
30. Grubman M.J., Baxt B. Foot-and-mouth disease. Clin. Microbiol. Rev. 2004, 17(2):465-493.
31. Knowles N.J., He J., Shang Y., Wadsworth J., Valdazo-Gonzalez B., Onosato H., Fukai K., Morioka K., Yoshida K., Cho I.S., Kim S.M., Park J.H., Lee K.N., Luk G., Borisov V., Scherbakov A., Timina A., Bold D., Nguyen T., Paton D.J., Hammond J.M., Liu X., King D.P. Southeast Asian foot-and-mouth disease viruses in eastern Asia. Emerg. Infect. Dis. 2012, 18(3):499-501.
32. Koev G., Kati W. The emerging field of HCV drug resistance. Expert Opin. Investig. Drugs 2008, 17(3):303-319.
33. Korneeva V.S., Cameron C.E. Structure-function relationships of the viral RNA-dependent RNA polymerase: fidelity, replication speed, and initiation mechanism determined by a residue in the ribose-binding pocket. J. Biol. Chem. 2007, 282(22):16135-16145.
34. Mort M., Convey I., Baxter J., Bailey C. Animal disease and human trauma: the psychosocial implications of the 2001 UK foot and mouth disease disaster. J. Appl. Anim. Welf. Sci. 2008, 11(2):133-148.
35. Nayak A., Goodfellow I.G., Woolaway K.E., Birtley J., Curry S., Belsham G.J. Role of RNA structure and RNA binding activity of foot-and-mouth disease virus 3C protein in VPg uridylylation and virus replication. J. Virol. 2006, 80(19):9865-9875.
36. Paarlberg P.L., Lee J.G., Seitzinger A.H. Potential revenue impact of an outbreak of foot-and-mouth disease in the United States. J. Am. Vet. Med. Assoc. 2002, 220(7):988-992.
37. Parniak M.A., Sluis-Cremer N. Inhibitors of HIV-1 reverse transcriptase. Adv. Pharmacol. 2000, 49:67-109.
38. Paton D.J., Valarcher J.F., Bergmann I., Matlho O.G., Zakharov V.M., Palma E.L., Thomson G.R. Selection of foot and mouth disease vaccine strains - a review. Rev. Sci. Tech. 2005, 24(3):981-993.
39. Poch O., Sauvaget I., Delarue M., Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 1989, 8(12):3867-3874.
40. Reid S.M., Ebert K., Bachanek-Bankowska K., Batten C., Sanders A., Wright C., Shaw A.E., Ryan E.D., Hutchings G.H., Ferris N.P., Paton D.J., King D.P. Performance of real-time reverse transcription polymerase chain reaction for the detection of foot-and-mouth disease virus during field outbreaks in the United Kingdom in 2007. J. Vet. Diagn. Invest. 2009, 21(3):321-330.
41. Rieder E., Bunch T., Brown F., Mason P.W. Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J. Virol. 1993, 67(9):5139-5145.
42. Rieder E., Henry T., Duque H., Baxt B. Analysis of a foot-and-mouth disease virus type A24 isolate containing an SGD receptor recognition site in vitro and its pathogenesis in cattle. J. Virol. 2005, 79(20):12989-12998.
43. Sanjuan R., Cuevas J.M., Furio V., Holmes E.C., Moya A. Selection for robustness in mutagenized RNA viruses. PLoS Genet. 2007, 3(6):e93.
44. Sanjuan R., Nebot M.R., Chirico N., Mansky L.M., Belshaw R. Viral mutation rates. J. Virol. 2010, 84(19):9733-9748.
45. Sarafianos S.G., Marchand B., Das K., Himmel D.M., Parniak M.A., Hughes S.H., Arnold E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 2009, 385(3):693-713.
46. Uddowla S., Hollister J., Pacheco J.M., Rodriguez L.L., Rieder E. A safe foot-and-mouth disease vaccine platform with two negative markers for differentiating infected from vaccinated animals. J. Virol. 2012, 86(21):11675-11685.
47. Vagnozzi A., Stein D.A., Iversen P.L., Rieder E. Inhibition of foot-and-mouth disease virus infections in cell cultures with antisense morpholino oligomers. J. Virol. 2007, 81(21):11669-11680.
48. Verdaguer N., Ferrer-Orta C. Conformational changes in motif D of RdRPs as fidelity determinant. Structure 2012, 20(9):1448-1450.
49. Wainberg M.A., Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279(24):1977-1983.
50. Weeks S.A., Lee C.A., Zhao Y., Smidansky E.D., August A., Arnold J.J., Cameron C.E. A Polymerase mechanism-based strategy for viral attenuation and vaccine development. J. Biol. Chem. 2012, 287(38):31618-31622.